BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [41] Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States
    Dodick, David W.
    Reed, Michael L.
    Lee, Lulu
    Balkaran, Bridget L.
    Umashankar, Kandavadivu
    Parikh, Mousam
    Gandhi, Pranav
    Buse, Dawn C.
    HEADACHE, 2024, 64 (04): : 361 - 373
  • [42] Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
    Insa, Samuel Diaz
    Guerrero, Angel
    Viguera, Javier
    Martinez, Vicente Medrano
    de Miguel, Carlos Calle
    Porta-Etessam, Jesus
    Ciudad, Antonio
    Diaz-Cerezo, Silvia
    Martin, Ana Roncero
    Nunez, Mercedes
    PAIN AND THERAPY, 2024, 13 (03) : 557 - 576
  • [43] Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials
    Zaazouee, Mohamed Sayed
    Ebrahim, Rokaya Y.
    Al-araj, Ghaida'a
    Zaki, Ibram
    Saad, Ahmed
    Farhat, Abdullah Mohamed
    Ali, Mustafa Hussein
    Elshennawy, Mohamed
    Fawy, Omar Khaled Fahmy
    Ahmed, Hadi F.
    Alahmad, Ziad
    Nada, Eman Ayman
    Abo-Hamra, Reem I.
    Elsnhory, Ahmed Bostamy
    Eleyan, Mohammed
    AbuEl-Enien, Hazem
    Elromely, Rasha Abdo
    AbdelQadir, Yossef Hassan
    Shah, Jaffer
    Elshanbary, Alaa Ahmed
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2024, 60 (01):
  • [44] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Yoshihisa Tatsuoka
    Takao Takeshima
    Akichika Ozeki
    Taka Matsumura
    Neurology and Therapy, 2021, 10 : 265 - 278
  • [45] Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
    Stauffer, Virginia L.
    Oakes, Tina M.
    Rettiganti, Mallikarjuna
    Day, Kathleen A.
    Camporeale, Angelo
    JOURNAL OF NEUROLOGY, 2021, 268 (05) : 1980 - 1980
  • [46] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Tatsuoka, Yoshihisa
    Takeshima, Takao
    Ozeki, Akichika
    Matsumura, Taka
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 265 - 278
  • [47] Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
    Virginia L. Stauffer
    Tina M. Oakes
    Mallikarjuna Rettiganti
    Kathleen A. Day
    Angelo Camporeale
    Journal of Neurology, 2021, 268 : 1980 - 1980
  • [48] Reversion of Patients with Chronic Migraine to an Episodic Migraine Classification with Fremanezumab Treatment
    Singh, Halker R. B.
    Cohen, J. M.
    Bibeau, K.
    Galic, M.
    Seminerio, M. J.
    Campos, Ramirez, V
    Ailani, J.
    HEADACHE, 2018, 58 : 70 - 71
  • [49] Reversion of Patients with Chronic Migraine to an Episodic Migraine Classification with Fremanezumab Treatment
    Cohen, Joshua M.
    Bibeau, Kristen
    Galic, Maja
    Seminerio, Michael J.
    Ramirez-Campos, Verena
    Singh, Rashmi B. Halker
    Ailani, Jessica
    ANNALS OF NEUROLOGY, 2018, 84 : S183 - S184
  • [50] Reversion of Patients With Chronic Migraine to an Episodic Migraine Classification With Fremanezumab Treatment
    Cohen, Joshua M.
    Bibeau, Kristen
    Galic, Maja
    Seminerio, Michael J.
    Campos, Verena Ramirez
    Singh, Rashmi B. Halker
    Ailani, Jessica
    NEUROLOGY, 2018, 90
12345